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ABSTRACT:  
Background: Disseminated tumor cells (DTCs) have been reported in the bone marrow 
(BM) of patients with localized prostate cancer (PCa). However, the existence of these 
cells continues to be questioned, and few methods exist for viable DTC isolation. 
Therefore, we sought to develop novel approaches to identify and, if detected, analyze 
localized PCa patient DTCs.  
Methods: We used FACS to isolate a putative DTC population which was negative for 
CD45, CD235a, alkaline phosphatase, and CD34, and strongly expressed EPCAM. We 












examined tumor cell content by bulk cell RNA sequencing (RNA-Seq) and whole exome 
sequencing after whole genome amplification. We also enriched for BM DTCs with α-
EPCAM immuno-magnetic beads and performed qRT-PCR for PCa markers.  
Results: At a threshold of 4 cells per million BM cells, the putative DTC population was 
present in 10 of 58 patients (17%) with localized PCa, 4 of 8 patients with metastatic PCa 
of varying disease control, and 1 of 8 patients with no known cancer, and was positively 
correlated with patients’ plasma PSA values. RNA-Seq analysis of the putative DTC 
population collected from samples above (3 patients) and below (5 patients) the threshold 
of 4 putative DTCs per million, showed increased expression of PCa marker genes in 4 of 
8 patients with localized PCa, but not the one normal donor who had the putative DTC 
population present. Whole exome sequencing also showed the presence of SNPs and 
structural variants in genes characteristic of PCa in 2 of 3 localized PCa patients. To 
examine the likely contaminating cell types, we used a myeloid colony formation assay, 
differential counts of cell smears, and analysis of the RNA sequencing data using the 
CIBERSORT algorithm, which most strongly suggested the presence of B cell lineages 
as a contaminant. Lastly, we used EPCAM enrichment and qRT-PCR for PCa markers to 
estimate DTC prevalence and found evidence of DTCs in 21 of 44 samples (47%). 
Conclusions: These data support the presence of DTCs in the BM of a subset of patients 
with localized PCa and describe a novel FACS method for isolation and analysis of 
viable DTCs.  
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INTRODUCTION: Prostate cancer (PCa) is the second most common cause of cancer-
related deaths of men in the U.S.1. Unlike most cancers, late recurrences in PCa are 
relatively common, with over 20% of recurrences occurring more than five years after 
curative intent radiation or surgery2. These recurrences are thought to result from early 
dissemination of PCa cells, which initially exhibit a dormant behavior for months or 
years, but eventually undergo re-activation and lead to clinical recurrence3,4. Many of 
these recurrences may result from distant cells, termed disseminated tumor cells (DTCs) 
or disseminated cancer cells (DCCs). To find the reservoir for dormancy and subsequent 
recurrence, investigators have noted PCa avidity for the bone microenvironment, with 
90% of fatal metastatic cases involving bone as one of the metastatic sites5.  
Previous investigators have found evidence of DTCs in the bone marrow (BM) 
from patients with localized PCa using various techniques including; RT-PCR for KLK3 
(PSA), immunocytochemistry for PSA or pan-cytokeratin, and immuno-magnetic 
enrichment and single cell isolation for EPCAM coupled with immuno-magnetic 
depletion of normal BM cells,4,6-24, as we recently reviewed25. However, most of these 
techniques did not allow isolation of viable cells for subsequent mRNA analysis. 
Furthermore, those that were able to isolate viable cells did not have the advantage of 
next generation sequencing technologies4,24. Most recently, investigators from four 
institutions were unable to detect DTCs in BM from localized PCa patients using four 
platforms validated for detection of circulating tumor cells (CTCs) from blood26.  
Therefore, to help reconcile these discrepancies in the literature, we designed 
novel techniques to detect DTCs in BM of patients with localized PCa, and if present 
estimate their frequency (i.e. number of putative DTCs per million marrow cells) and 












prevalence (i.e. percentage of localized PCa patients with detectable DTCs). Furthermore, 
because we ultimately hope to use these techniques to understand the biology of PCa 
dormancy and recurrence, we desired to isolate viable DTCs so that RNA could be 
extracted.  
Therefore, to detect and isolate viable BM DTCs from localized PCa patients, we 
designed a fluorescence activated cell sorting (FACS) based protocol and chose high 
expression of EPCAM as our positive marker, combined with negative markers for 
possible contaminating BM cell types with no reported expression in PCa cells: CD45 
(PTPRC) for hematopoietic cells, CD235a (Glycophorin A) for erythroids, alkaline 
phosphatase (ALPL) for osteoblastic lineage cells, and CD34 for hematopoietic stem and 
progenitor cells. As an additional estimate of the prevalence of BM DTCs in localized 
PCa, we also did a simple immuno-magnetic enrichment for EPCAM and performed 
qRT-PCR for expression of prostate markers.  
Here, using cell enumeration by flow cytometry, bulk cell RNA-Sequencing, 
whole genome amplification followed by whole exome sequencing, and qRT-PCR, we 
show evidence for the presence of DTCs in the BM of a subset of patients with localized 
PCa. These cells are rare, with a frequency less than 1 putative DTC per 105 viable, 
nucleated bone marrow cells in most patients. Our findings are in agreement with the 
majority of the literature that does find DTCs to be present in some patients with 
localized PCa, although at a lower prevalence (% of patients) than some reports, which 
have been as high as 72% of patients12. Perhaps more importantly, we have developed 
methods using standard FACS equipment to isolate viable PCa DTCs. We expect this 
technical advance to be a boon for investigators studying PCa recurrence.  












MATERIALS and METHODS: Patients and sample collection: Patient characteristics 
are summarized in Table I. The use of localized PCa samples for the complimentary 
approaches is summarized in Figure 1. All subjects provided written informed consent as 
a part of IRB approved protocols. All patients with localized PCa (AJCC 8th Edition 
Stage IIIC or less) underwent a radical prostatectomy as their initial treatment of PCa. 
Any localized PCa patient who received neoadjuvant (before surgery) treatment was 
excluded from FACS analysis. All samples from patients with localized disease were 
collected by bone marrow aspiration at Johns Hopkins University either before their 
surgery from the posterior superior iliac crest, or at the time of surgery from the pubic 
bone. Samples were transferred to 7.5 ml EDTA (purple cap) tubes and shipped overnight 
to The University of Michigan on wet ice. Normal marrow samples were purchased from 
All Cells (Alameda, CA), drawn from the posterior superior iliac crest of paid donors, 
transferred to heparinized tubes and shipped overnight on wet ice, or aspirated from 
vertebrae into EDTA tubes during non-cancer spine surgeries at the University of 
Michigan. Samples from patients with metastatic (all castration resistant) PCa were 
collected at the University of Michigan by aspiration of the posterior superior iliac crest 
into EDTA tubes (living donors) or en bloc during bisection of the femur or vertebrae at 
autopsy as part of the Michigan Legacy Tissue Program (rapid autopsy program). 
Autopsy specimens were homogenized to release cells for analysis.  
Anti-EPCAM bead enrichment, mRNA isolation, and qRT-PCR: Enrichment of 
DTCs from 1 ml of bone marrow aspirate was performed as described for peripheral 
blood27. Briefly, cells were bound to anti-EPCAM magnetic beads, washed, and directly 
lysed. Messenger RNA was captured with Oligo(dT) 25 mRNA Dynabeads (Thermo 












Fisher Scientific) and reverse transcribed into cDNA. Primer sequences were as 
previously described27, and all pairs except KLK2 cross exon boundaries. 
Preamplification of up to 18 genes including controls was performed followed by qRT-
PCR and relative quantification by the ΔΔCt method.  
DTC enrichment and/or isolation by FACS: Marrow aspirates were mixed 1:1 
with PBS, layered onto Ficoll and centrifuged at 500 x G for 30 minutes to isolate the 
buffy coat / nucleated population. Subsequent steps were performed in cold flow 
cytometry buffer (PBS with 2% FCS and 1 mM EDTA). The cells were washed and 
stained for 1 hour with the following antibodies; PE-Cy7 α-CD235a diluted 1:20 
(BioLegend #349112), Brilliant Violet 605 α-CD34 diluted 1:20 (BioLegend #343529), 
APC α-EPCAM diluted 1:20 (BD #347200), PerCP-Cy5.5 α-alkaline phosphatase diluted 
1:20 (BD #561508) and PE α-CD45 diluted 1:5 (BD #555483). Cells were washed and 
resuspended in flow buffer containing 0.5 µg/ml DAPI and passed through a 40 µm filter 
to create a single cell suspension for FACS. All analyses were performed on a BD FACS-
Aria IIu instrument with 405, 488 and 630 nm lasers. EPCAM positivity was defined as 
higher than unstained or isotype control stained cells. EPCAMhigh was defined as at least 
5x more intense than the center of the adjacent “dim” population. The putative DTC 
population was selected from single, viable cells as double negative on a plot of CD45 vs. 
CD235a, then negative for alkaline phosphatase, then negative for CD34 and with high 
surface expression of EPCAM on a plot of CD34 vs. EPCAM (Figure 2A). Sorted cells 
were collected in 10% FCS RPMI in a 0.2 ml tube, washed with cold PBS, leaving 
behind ~10 µl per tube. 10,000 units of RNAse inhibitor (Invitrogen #55518-012) were 
added, followed by freezing in liquid nitrogen.  












Bulk RNA-Sequencing: FACS isolated marrow samples or 100 C42B cells as a 
positive control were processed without initial RNA purification using the Takara 
SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (#634889). cDNA was 
amplified between 8 and 15 cycles depending on cell number, followed by 16 cycles of 
library amplification with mRNA optimized methods. 40 million 50-cycle single end 
reads were obtained on an Illumina HiSeq-4000 instrument. FastQC was used to assess 
read quality. Data was processed using published methods28. Briefly, RNA-Seq reads 
were aligned to the GRCh38 genome using HiSAT2 (v 2.1.0)29. Stringtie (v 1.3.4) was 
subsequently used to assemble and quantify transcripts from the alignment data30. 
Individual data files were converted to transcripts per million (TPM).  
Analysis of gene expression data: Morpheus software (Broad Institute) was used 
for visualization and hierarchical clustering of gene expression data using default 
parameters. Gene ontology analysis was conducted with GSEA software (Broad Institute) 
of the c5.bp.v6.2 gene sets, parameter metric Diff_of_classes, using 5 permutations. The 
CIBERSORT algorithm31 (Stanford University) was used to estimate the identity of any 
immune cells present in RNA-Seq data. Data was uploaded as a text file of TPM values. 
Data was analyzed using the LM22 (default) signature gene file and the “absolute” mode 
with 100 permutations.  
Whole genome amplification and whole exome sequencing: Samples were 
processed directly after FACS with no intervening DNA purification. 100 PC3 cells were 
used as a positive control. Whole genome amplification was performed with the Qiagen 
single cell Repli-g kit (#150343). Libraries were constructed using an Agilent 
SureSelectXT Human All Exon V6 kit. Sequencing was performed to ~100x coverage on 












an Illumina HiSeq PE150 instrument with 40 million paired end reads per sample. 
Somatic SNPs were analyzed using MuTect2 software (Broad Institute) tumor vs normal 
approach with CD45+ cells from the same patient as the control for each putative DTC 
sample. The tumor only approach was used for PC3 cells. Manta software (omicX; 
Rouen, France) was used for structural variant analysis again using the tumor vs. normal 
approach except for PC3 cells. We queried a list of the following 75 genes know to be 
altered in PCa; PTEN, ZNF292, TP53, FOXA1, ERG, CDKN1B, NEAT1, PDE4D, 
ROBO2, PPAP2A, ETV3, MLL3, SPOP, MYST3, CDH12, KMT2C, PPP2R2A, ADAM28, 
IL6ST, UBTF, AR, APC, GPATCH8, ASH1L, DLC1, NCOR2, ZFHX3, TBL1XR1, 
SENP6, ANTXR2, ARID4B, ASXL2, LCE2B, DOCK10, NDST4, RPL11, RB1, USP28, 
ARID1A, CASZ1, CNOT3, ATM, PIK3R1, BRCA2, TBX3, ZMYM3, CDK12, KDM6A, 
NCOR1, CTNNB1, SMAD2, SMAD4, AKT1, BRAF, HRAS, IDH1, KMT2D, MLL2, 
MTUS1, PIK3CA, PIK3CB, RNF43, FOXP1, SHQ1, RYBP, CDH1, ROBO1, ZBTB16, 
NCOA7, MYC, MAP3K1, LRP1B, PPE4D, CSMD3, and NKX3-132. We reported those 
genes with a SNP or structural variant in the putative DTC sample but not in the internal 
control.  
Cell smear morphologic analysis: Cells were dried on slides, then fixed and 
stained using the Hema-3 kit (Fisher Scientific). 500 cell counts were performed by a 
blinded pathologist.  
Hematopoietic colony formation: 24 well plates were seeded with 1000 flow 
events per well and then combined with 500 µl of methylcellulose media with 
hematopoietic growth factors (Stem Cell Technologies, H4434 Classic #13M53790). 
Cells were cultured under standard conditions for 7 days without disruption and then 












photomicrographed. CFU-E, CFU-GM and CFU-GEMM colonies were counted by a 
blinded observer.  
Statistical analyses: Comparison of 2 groups was performed in GraphPad Prism 
software by 2 samples unpaired Student’s t-test. Linear regression was used to assess 
correlation between putative DTC percentage and patient [PSA]. Histograms were 
generated using SAS software.  
RESULTS: We analyzed bone marrow samples from 72 patients with localized PCa, 8 
patients with metastatic prostate cancer (6 living donors, and 2 rapid autopsy patients), 
and 8 patients with no known cancer as negative controls (6 iliac crest aspirates from paid 
donors and 2 vertebral marrow samples from non-cancer spine surgeries) (Table I). There 
was incomplete clinical data for two of the localized PCa patients. The living donor 
metastatic PCa patients all had treated castration resistant disease and had varying 
degrees of disease control at the time of donation as approximated by their plasma PSA 
level. Four were well controlled with PSA values < 6 ng/ml. As described in more detail 
below, the samples were analyzed using either multi-color FACS followed by 
downstream analyses on the isolated cells, or enrichment of EPCAM+ cells with immuno-
magnetic beads followed by qRT-PCR for PCa markers (Figure 1). To maximize the data 
collected from these valuable human samples, we split samples between immuno-
magnetic bead enrichment (1 ml of marrow aspirate) and FACS analyses (5 – 6 ml) as 
limited by personnel and equipment availability. Therefore, some patients have data for 
both the immuno-magnetic bead and FACS based approaches.  
Our FACS based method utilized negative markers for erythroid lineage cells 
(CD235a), hematopoietic stem and progenitor cells and endothelial cells (CD34), 












osteoblastic lineage cells (alkaline phosphatase) and set a high threshold for EPCAM 
positivity (Figure 2A). To dichotomize the presence of putative DTCs, we set a threshold 
of greater than 4 cells per million single, viable, BM cells. This threshold was selected at 
a local minimum of a histogram of the frequency of these cells in all samples (Figure 2B, 
red line and arrow). Based on the current data, this seemed to be the most reasonable 
threshold, but we acknowledge that this threshold line could shift slightly if data from 
more patients were acquired. Furthermore, because of the possibility that DTCs were less 
numerous than 4 per million, we continued to collect and subsequently analyze the 
putative DTC population in samples with lower cell frequencies if at least 20 cells could 
be sorted. Because of the rarity of these cells we were limited to collect a maximum of 
300 cells from a tube of marrow from localized PCa patients but were able to collect 
more from some metastatic patients. Using this threshold of > 4 per million cells, we 
detected the presence of the putative DTC population in 4 of 8 metastatic PCa patients, 
10 of 58 localized PCa patients, and 1 of 8 normal donors (Figure 2C). In support of a 
malignant identity for the putative DTC population, we also noted that the putative DTC 
frequency is significantly correlated with localized PCa patients’ plasma PSA 
concentration; a predictor of recurrence33. Clinical recurrence data for this patient cohort 
will take years to mature.  
In interpreting these results, we note that some of the metastatic PCa patients were 
under good disease control (PSA < 6 ng/ml) at the time of sample collection (Table I). 
The four metastatic patients with PSA > 6 ng/ml all had a putative DTC population 
frequency > 4 cells per million, whereas the metastatic patients with PSA < 6 ng/ml had 
DTC population frequencies < 4 cells per million. With regard to the one normal donor 












with this population present above threshold, we also note that these methods could 
theoretically detect most epithelial cancers and at present we are unable to exclude this 
possibility. Further, marrow from this normal donor subject (AC_6297) demonstrated no 
molecular evidence of PCa marker gene expression by RNA-sequencing (Figure 3A) or 
qRT-PCR (Figure 6A) – thus suggesting a false-positive result not due to PCa cells.  
To evaluate the tumor identity of the putative DTC population, we analyzed 
sorted cells from 8 localized PCa patients by bulk RNA-sequencing. Three of these 
patients (JH3998, JH2695, and JH2517) had a putative DTC frequency above the 
threshold of 4 cells per million, and five patients (JH3707, JH3756, JH3783, JH3902, and 
JH4548) were below this FACS threshold. As a comparator for these analyses, we 
included the putative DTC population from the one normal donor patient that had the 
putative DTC population present. We also used the C42B cell line as a positive control 
(Figure 3A). The localized PCa samples are ordered for presentation by decreasing KLK3 
(PSA) expression from left to right. In keeping with the well-established role of PSA as a 
PCa marker, several other potential PCa marker genes follow the same pattern as PSA. 
None of the right-most samples (lowest PSA expression) have expression of the PCa 
marker genes higher than the normal donor sample, with the exception of one sample 
with KRT18 expression (patient JH_2695). We interpret this data that four of the eight 
localized PCa samples had expression of PCa marker genes consistent with the presence 
of PCa cells. Importantly, the one normal donor sample had no evidence of expression of 
PCa marker genes. We also analyzed this data set with gene ontology analyses using gene 
set enrichment analysis (GSEA) methods. Here, we compared the gene expression of the 
four localized PCa samples with the highest PSA values vs. the one normal donor patient 












with this population present. Again, in keeping with the presence of PCa cells in the 
putative DTC population we noted the highest level of enrichment for the “Cellular 
Response to Steroid Hormone Stimulus” and “Intracellular Steroid Hormone Receptor 
Signaling Pathway” gene sets (Figure 3B). We found this to be notable given the 
importance of testosterone and other steroid hormones in PCa. Conversely, when we 
compared putative DTC gene expression of the one normal donor to the PCa patients we 
observed the highest level of enrichment for two immune related gene groups; 
“Immunoglobulin Production” and “Production of Molecular Mediator of Immune 
Response,” consistent with the presence of marrow cells in these samples.  
For further validation of the tumor origin of cells in the putative DTC population, 
we performed whole genome amplification and whole exome sequencing to ~100x 
coverage of leukocytes and between 100 and 250 putative DTCs from three localized 
PCa patients, one metastatic patient as a FACS control, and the PC3 cell line as a 
sequencing technical control. The metastatic patient (UM_1560) and two of the localized 
patients (JH_4797, and JH_4905) had > 4 putative DTCs per 106 BM cells, and localized 
patient JH_5557 had 3 putative DTCs per 106 BM cells. The leukocyte (CD45+) 
population was used as an internal germline and technical control for each patient. To 
determine if these populations contained small alterations characteristic of PCa, we 
focused our analysis on a list of 75 genes previously reported to be altered in PCa (gene 
list in methods)32. Figure 4A reports genes from this list which had either single 
nucleotide polymorphisms (SNPs) or gene level structural variants (SVs) in the putative 
DTC population but not in the corresponding internal leukocyte control. We observed 
alterations of genes characteristic of PCa in metastatic sample and 2 of the 3 localized 












PCa putative DTC samples. Unfortunately, the data across the genome was not 
sufficiently uniform to visualize chromosomal level alterations (deletions, amplifications, 
and translocations), likely due to unequal amplification, which has been reported 
previously with the Repli-G whole genome amplification system34. Lastly, to gain an 
appreciation for the approximate fraction of cancer cells in the putative DTC population, 
we examined the allele frequency for SNPs. The allele frequency was lower for the 
localized PCa samples than the metastatic sample, suggesting the continued presence of a 
normal marrow population at a higher fraction in the localized samples than the 
metastatic sample (Figure 4B). We did not analyze the allele frequency for SVs because 
it is more difficult to estimate with the bioinformatics methods used. 
In order to improve isolation methods and to guide selection of any additional 
negative markers for future protocol refinement, we further examined the contaminating 
marrow cell types in sorted populations (Figure 5). We first performed myeloid colony 
formation assays to assess the cell types present (Figure 5A). The putative DTC 
population from a localized PCa patient does not yield enough cells for most in vitro 
assays. Therefore, to achieve a usable number of cells, we decreased the stringency of the 
EPCAM gate to yield a population we refer to as “DTC plus,” which is like putative 
DTCs but also includes EPCAM dim cells in addition to EPCAM high expressing cells. 
For comparator cell populations, we also isolated CD34+ cells, CD45+ cells, and “2 
marker” cells which were CD45- / EPCAM dim or hi but did not include the other negative 
markers. The “DTC plus” population showed lower numbers of myeloid colonies than 
the “2 marker” population – consistent with contaminating non-myeloid cells in the 
putative DTC population. We also analyzed the same populations by morphology on cell 












smears (Figure 5B). We observed low numbers of granulocytes in the “DTC plus” 
population but a higher number of “atypical cells” with an appearance consistent with 
plasma cells, erythroid precursors or tumor cells. Then, using the RNA-Seq data set first 
described in Figure 3, we used the CIBERSORT algorithm to estimate the immune cell 
composition in these samples31. The samples are again arranged in decreasing order of 
PSA expression for the localized PCa samples (Figure 5C). In agreement with the 
morphological analyses, this highlighted the presence of B-cell sub-sets, especially of 
plasma cells. We noted a higher estimated content of plasma cells in the samples on the 
right side of the heat map, which also have lower expression of PCa markers – thus 
consistent with an increased percentage of plasma cells in samples where the DTC 
content appears lower. Importantly, the patient with the highest apparent PCa content in 
Figure 3A (JH_3756) also had the lowest estimated immune cell fraction. Overall, these 
analyses further support the PCa marker data from Figure 3 and highlight non-myeloid 
cells, especially plasma cells, as potential contaminating cell types of our putative DTC 
population.  
Lastly, to achieve another estimate of the prevalence of bone marrow DTCs in 
localized PCa, we used α-EPCAM magnetic bead enrichment and multiplex qRT-PCR 
for PCa markers to assess the presence of DTCs in 44 localized PCa patients and 4 
normal marrow donors (Figure 6). We previously developed these techniques for 
peripheral blood and reliably detected ≥ 10 PCa cells27. In the current work, we observed 
upregulation of one or more PCa-related genes in approximately half of the localized PCa 
samples as compared to the normal donor controls (Figure 6A). Importantly, the one 
normal donor with the putative DTC population present on FACS (AC_6297) was one of 












these normal controls and did not show increased PCa marker gene expression. To 
objectively separate putative DTC positive vs. DTC negative patients we analyzed the 
localized PCa patient data with hierarchical clustering and observed segregation into 
three main trunks (Figure 6B). After clustering analysis, we interpreted the outer two 
trunks as positive – labeled “Positive 1” or “Positive 2” (collectively 21 of 44 samples or 
47%) and the center trunk as less likely to contain DTCs – labeled “Negative” or 
“Equivocal.” The six patients labeled “Equivocal” cluster with the “Negative” patients 
but also share characteristics with “Positive 2.” Thus a less conservative interpretation of 
the data would estimate DTC prevalence at 27 of 44 (61%). We noted that the “Positive 
1” trunk was characterized by expression of the pathognomonic PCa fusion gene 
TMPRSS2-ERG and that the “Positive 2” trunk was characterized by expression of PCA3 
and SCHLAP1. When the same data was analyzed and presented as the mean gene 
expression for all patients in each gene expression cluster, we observed increased 
expression relative to normal donor marrow of 6 of the 8 PCa genes in “Positive 1” and / 
or “Positive 2” but not in the “Negative” gene expression group (Figure 6C).  
Utilization and results from all of the PCa patient and normal donor samples is 
summarized in Table II. Because the EPCAM bead enrichment and qRT-PCR panel, 
some patients have PCR data and either RNA-Seq or DNA sequencing data. Not all 
patients have molecular data available.  
DISCUSSION: Here we present multiple lines of evidence indicating BM DTCs are 
detectable in many men with localized PCa and describe a novel method for their 
enrichment and collection by FACS – a widely available technique. This study provides 
important information on the anatomic distribution of PCa cells in clinically localized 












disease. At a threshold of 4 putative DTCs per 106 BM cells, we conservatively estimate 
the prevalence of DTCs at 10/58 patients (17%). However, as shown by our RNA-Seq 
data, some patients with a detectable putative DTC population below this threshold are 
likely to contain DTCs as well, although their isolation becomes increasingly difficult 
with current methods. Using qRT-PCR for a panel of PCa marker genes, after EPCAM 
bead enrichment, we estimate the prevalence of DTCs at 21/44 (47%). Perhaps the real 
prevalence lies somewhere in the middle. Nevertheless, we feel given the current data it 
is reasonable to posit that at least some PCa patients do have bone marrow DTCs at the 
time or radical prostatectomy. We think that these results lend additional insight into the 
field of PCa dormancy and recurrence, and provide an invaluable tool for investigators 
studying these processes. These essential techniques could be used in the current form for 
additional downstream analyses in subsequent work or could serve as the basis for further 
refinements in DTC isolation.  
This work must be placed in the context of prior research on PCa DTCs, as rates 
of detection have ranged from near zero to 72% of localized patients (reviewed in25). 
Prior to 2018, investigators have reported the presence of DTCs using independent 
methodologies including; RT-PCR for KLK3 (PSA), immunocytochemistry for PSA or 
pan-cytokeratin, and EPCAM based immune-magnetic enrichment and single cell 
isolation coupled with negative depletion of leukocytes and megakaryocytes. At least one 
work using each of these techniques has also shown correlation of DTC detection with 
patient data on recurrence or risk of recurrence.25 Additionally, our data should be 
considered in the context of a recent study in which PCa DTCs were very rarely detected 
at the time of radical prostatectomy (Chalfin et al)26. It is challenging to prove the 












absence of a cell population, as suggested in the study by Chalfin and colleagues, and is 
also difficult to know the sensitivity of their methodologies. This is particularly true 
given the use of semi-automated platforms which had been previously validated for the 
detection of circulating tumor cells (from peripheral blood) rather than for DTCs, and 
with minimal assessment of positive controls for DTC detection. The unexpected findings 
of the Chalfin study highlights the need for further confirmatory investigation , such as 
ours, in part to provide balance. The bulk of the literature supports that BM DTCs are 
present in some patients with localized PCa – as we have recently reviewed25. However, 
very little is known of the phenotype and behavior of these cells – which will be greatly 
aided by the techniques for viable cell isolation that we present here. With a few 
exceptions from groups at the University of Regensburg and University of 
Washington4,7,8,18,24, prior investigations of PCa DTCs did not isolate viable cells6,9-11,13-
17,19-23.  
Key limitations of the current study include the relatively small sample size and 
the difficulty isolating sufficient numbers of cells for genetic analyses. Single cell rather 
than bulk NGS analyses would also be useful but are a significant technical challenge 
also because of the rarity of the cells. The commonly used single cell platforms from 
Fluidigm and 10x Genomics require many input cells; on the order of 104 or 105 – a 
hundred or thousand fold more DTCs than are likely to exist in a tube of marrow from a 
localized PCa patient.  
An additional limitation of this study is the continued use of EPCAM to help 
identify DTCs, as EPCAM can lead to both false positives and false negatives. Chery et 
al4 used single cell micro-array analyses on DTCs isolated using EPCAM based methods 












and observed significant EPCAM expression by normal bone marrow cells4. 
Furthermore, DTCs in the bone marrow may downregulate EPCAM as they assume a 
mesenchymal or stem-like phenotype35,36. We acknowledge that some DTCs with a stem 
or mesenchymal phenotype might not be captured by our current FACS methods. 
However, we did not think it possible to empirically choose a marker for mesenchymal 
phenotype DTCs at the onset of this work and hoped to refine our techniques based on 
data. We think that the data presented here provides an invaluable framework, with which 
to add additional positive or negative markers in future studies. Our RNA-Seq data is 
useful this regard. Of the cell surface genes, prostate stem cell antigen (PSCA) appears to 
be highly expressed in DTCs, though analysis of additional patients will be useful. Our 
work examining the potential contaminating cell types highlights the presence of plasma 
cells and therefore suggests potential use of plasma cell negative markers. Our data are 
not inconsistent with the presence of contaminating erythroid precursors as well, as 
another group previously reported4. Together, these data suggest that while normal 
marrow residents may express EPCAM, higher levels of expression can nevertheless 
provide valuable information on the presence of DTCs and allow for continued 
improvement in understanding their biology and how best to isolate them.  
CONCLUSIONS: We present multiple lines of evidence demonstrating the presence of 
bone marrow DTCs in localized PCa patients at the time of radical prostatectomy. 
Although the fraction of positive patients is perhaps lower than previously reported, 
DTCs are present in at least some patients at the time of prostatectomy – which provides 
a clear rationale for further investigation of the bone marrow as a reservoir for PCa 
recurrence and for the eventual development of therapies targeted to this site. Lastly, we 












provide an invaluable tool for viable DTC isolation to better understand the biology of 
this process – which we hope will lead to fewer cases of deadly recurrent PCa.  
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FIGURES 
Figure 1: Use of localized PCa samples in complimentary analytic approaches. 
Fluorescence activated cell sorting (FACS) with multiple markers followed by molecular 
or morphologic analysis of sorted cells (top), or enrichment with immuno-magnetic beads 
for EPCAM positive cells and multiplex qRT-PCR (bottom).  

























Figure 2: Analysis and isolation of putative DTCs using multi-parameter FACS. A, Flow 
cytometry markers and gating strategy. B, Histogram of the frequency of putative DTCs 
per 106single, viable, BM cells from all sample types: normal donors; n = 8, localized 
PCa; n = 58, and metastatic PCa; n = 8. A red threshold line is drawn at a local minimum 
at 4 cells per 106 where no data points were present. C, Frequency of the putative DTC 
population in normal donors, localized PCa patients and metastatic PCa patients. The red 
dotted line indicates the FACS positive threshold of 4 cells per 106. D, Correlation of 
localized PCa patient DTC frequency vs. blood PSA concentration by linear regression 
analysis.  

























Figure 3: Examination of BM putative DTC expression profiles by RNA Sequencing. A, 
Heat map of relative TPM values of proposed PCa marker genes from samples of the 
FACS population containing putative DTCs. Samples are color coded as follows: gray; 
the one control patient with this population, orange; C42B cell line as a positive control, 
and blue; 8 Localized PCa patients. The localized PCa samples are ordered from left to 
right in decreasing order of KLK3 (PSA) expression. B, Gene ontology analysis using 
GSEA software comparing the 4 highest KLK3 expressing localized PCa samples relative 
to the normal donor sample. Top: gene sets with the 10 highest normalized enrichment 
scores are listed. Bottom: Enrichment plots for the gene sets with the two highest 
normalized enrichment scores. C, Results from the gene ontology analysis shown in (B), 
for gene sets enriched in the normal donor relative to the localized PCa patient samples.  

























Figure 4: Whole genome amplification and whole exome sequencing of the putative 
DTC population. A, Map showing somatic single nucleotide polymorphisms (SNPs) or 
small structural variants (SVs), detected in each experimental sample but not CD45+ cells 
from the same patient as an internal control. Sample types are annotated as follows: gray; 
PC3 PCa cell line, orange; metastatic PCa patient, yellow; 3 localized PCa patients. 
Detected alterations are indicated by: white; no alteration detected, blue; SNP detected, 
red; SV detected, purple; SNP and SV both detected. All genes were selected from a list 
of 75 genes previously reported to be altered in prostate cancer. B, Allele frequencies for 
SNPs detected in the PCa putative DTC samples and PC3 cells. The median allele 
frequency for each sample is listed in the bottom row.  

























Figure 5: Identity of contaminating cell types. A, Estimation of the number of 
contaminating myeloid precursors by colony formation. Upper left; example images of 
each colony type. Upper right; Example FACS plots describing the cell populations 
examined. Data are a representative experiment mean ± SD of the six rows of a 24 well 
plate. Means were compared by Student’s t-test. B, Estimation of contaminating cell 
types by morphology. Top: Hema3 (Wright-Giemsa) stained smears prepared after 
sorting the indicated cell populations: Bottom: 500 cell marrow differential cell counts 
were performed by a blinded observer of smears from five patients. Data represent mean 
± SEM. C, Estimation of immune cell content in the putative DTC population from the 
RNA-Seq data (as in Figure 3) using the CIBERSORT algorithm.  

























Figure 6: Evaluation of localized PCa DTCs by anti-EPCAM bead enrichment and qRT-
PCR. A, Expression of 8 potential PCa marker genes in bone marrow from 44 patients 
with localized PCa (light blue) relative to four bone marrow donors with no known 
cancer (orange). B, Hierarchical clustering of marker gene expression in the PCa patients. 
Of the three main clusters, the outside two clusters are hypothesized to contain DTCs 
(“Positive 1” (blue) and “Positive 2” (purple)). The middle cluster is hypothesized to be 
“Negative” (yellow) or “Equivocal” (green) for the presence of DTCs. The three main 
clusters are indicated by the tree above, and brackets below the heat map. C, Mean ± 
SEM expression of the marker genes grouped by healthy donor or the four PCa patient 
expression clusters. 






























Localized Prostate Cancer Patients Metastatic Prostate Cancer Patients 
  Criterion Subjects (n)   Criterion Subjects 
(n) 
Total - 72 Total - 8 
Age (years) 
≤ 59 19 
Age (years) 
≤ 59 3 
60 -69 39 60 -69 3 








≤ 6 4 
6.01 - 10 28 6.01 - 10 1 
10.01 - 20 8 10.01 - 20 0 
> 20 2 > 20 3 
Prostatectomy 
Gleason score 
6 3   Iliac crest 6 
3+4 = 7 45 Collection site Vertebrae 1 
4+3 = 7 12   Femur 1 
8 - 10 10 
Patients with no Known Cancer 
Tumor stage 
pT2 41 
pT3a 23   Criterion Subjects 
(n) 









≤ 29 4 
Positive 13 ≥ 30 4 
Collection site 
Iliac crest 27 
Collection site 
Iliac crest 6 
Pubis 43 Vertebrae 2 
 
Table I: Patient characteristics 












































Normal donor DTC 
negative 7 0 0 0 0 0 0 3 
Normal donor DTC 
positive 1 1 0 1 0 0 0 1 
Localized PCa DTC 
negative 48 8 3 2 1 1 11 13 
Localized PCa DTC 
positive 10 9 1 2 1 0 1 5 
Localized PCa No FACS 
data 14 0 0 0 0 0 10 4 
Metastatic PCa DTC 
negative 4 0 0 0 0 0 0 0 
Metastatic PCa DTC 
positive 4 4 0 0 1 0 0 0 
 
Table II: Results summary. Left column “Negative” and “Positive” denote either less 
than 4 putative DTCs per million BM cells or more than 4 putative DTCs per million BM 
cells respectively. “RNA-Seq positive” denotes increased expression of PCa marker 
genes on RNA sequencing of putative DTCs. “WGA / WES positive” denotes the 
presence of mutations in PCa genes after whole genome amplification and whole exome 
sequencing.  
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